Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.
about
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectImmunotherapy in acute leukemiaGraft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality.Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling DonorsTrying to overcome residual disease after bone marrow transplantation for hematologic malignancies.Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remissionCD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cellsRecognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populationsAugmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.Suicide gene therapy for graft-versus-host disease.Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.Chronic myeloid leukemia as an immunological target.Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia.Human hematopoietic cells and thymic epithelial cells induce tolerance via different mechanisms in the SCID-hu mouse thymus.The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting.Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
P2860
Q26826830-D649D7D9-84DD-45F2-9859-709ABA5A69A9Q33731552-1B693668-F7AF-4715-8BCF-5027757B5633Q33788194-4646508F-842A-4CF7-A0D9-F59B5E5FC2CAQ34089112-1233950D-309A-4D58-9827-A99687A3B1CAQ34163218-1AFFB4E7-D574-40C5-A0AD-63087A121E69Q34207168-50A40421-100D-4B7C-B882-B4EE37266245Q34314427-8570A930-436E-479E-95FE-6110354421CBQ35169842-D28E7D42-EDFD-4342-A121-3853C6D2C6DBQ35181654-2ABF1CE2-836C-4D8A-8229-FB84F834C159Q35558987-DB9A9C4F-0875-4DEF-81C8-AE9707F3A716Q35752628-186B89BA-C786-41D7-8CD1-261B145A0F71Q35865440-B13B8653-6462-4E02-B39E-8BFA9E903559Q36662079-660CCD49-93E1-4504-B8E9-DA842AA62D24Q37242561-D05B4B7D-75DC-4F6D-BC81-A77763BC6023Q37486793-D3005920-AB66-4D39-81EF-8E7F1209677EQ37773293-19B0269E-1232-4392-88AC-889337133835Q39205106-164B3659-AF43-44C3-8C77-DDD5B0A3FD1EQ40536673-77715F6F-DBB6-4621-AA55-0E82EFE64084Q40916271-3DF66719-0F84-4CFC-B6C1-087980D1A9C5Q41561760-E836DB03-3812-4111-87CE-BD06FD164EB4Q41823203-E46A7794-14B7-402C-83AA-CED1D1E07A93Q42944891-D81F3D57-8165-4E18-BDDA-B8C46D42F063Q45722889-1BA7A265-EE86-4898-9953-D1D9344E6F01Q48523192-2843C205-BB1B-453B-8837-087528421F00Q51028658-9FDD8B0E-F58C-418F-804B-154FF4F5AA5A
P2860
Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@ast
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@en
type
label
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@ast
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@en
prefLabel
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@ast
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@en
P2093
P2860
P356
P1476
Growth inhibition of clonogeni ...... cific cytotoxic T lymphocytes.
@en
P2093
Falkenburg JH
Goselink HM
Kooy-Winkelaar YM
Willemze R
de Kroon J
van Luxemburg-Heijs SA
van der Harst D
P2860
P356
10.1084/JEM.174.1.27
P407
P577
1991-07-01T00:00:00Z